Osveh Pharmaceutical Company

What Osveh Pharmaceutical Company does

Osveh Pharmaceutical Company (شرکت داروسازی اسوه) is an Iranian publicly listed pharmaceutical manufacturer founded in 1966 (Solar Hijri 1345) and operational since 1969–70, headquartered in Tehran on an 18,000-square-meter campus with 10,580 square meters of built production, laboratory, and warehouse space. Originally established as 'Iran Merek Company' (ایران مرک), it later rebranded and converted to public joint stock status, now trading on the Iran Stock Exchange (بورس) as part of the Hefadaro Pharmaceutical Holding (هلدینگ شفادارو). The company manufactures human pharmaceutical products across a broad therapeutic footprint — cardiovascular, neurology (including multiple sclerosis), nephrology, oncology, hematology, immunosuppression, internal medicine, and dietary supplements — and across multiple dosage forms including pre-filled syringes, effervescent tablets, ampoules, capsules, tablets, and vials. Its branded portfolio includes Osvimber (Glatiramer Acetate), Osoral/Osveral (Deferasirox), Osvex/Osvix (Clopidogrel), Imatinib, and Sunitent (Sunitinib), with explicit positioning in orphan drugs (داروهای اورفان) and exclusive products (داروهای انحصاری).

The business operates a professional B2B go-to-market model: enterprise field-sales representatives target physicians, hospitals, and healthcare institutions across Iran, supported by a physician portal with specialty-specific scientific articles and patient education resources. Distribution runs through Iran's domestic pharmaceutical wholesale network to retail and institutional pharmacies. Pricing is set via Iran's national pharmaceutical pricing mechanism rather than negotiated enterprise contracts. The company was ranked among Iran's top 20 pharmaceutical manufacturers by total sales for Tir 1405 (June–July 2026), and parent Hefadaro Holding reported a 164% increase in Rial value of production alongside a 4.2% increase in Rial market share — figures likely reflecting Iran's high-inflation nominal environment rather than real unit-volume growth. Geographic footprint is single-country (Iran) with no disclosed international expansion, and operating geography is concentrated in the Middle East / IRN jurisdiction.

Name

Osveh Pharmaceutical Company

Legal name

Osveh Pharmaceutical Company (Public Joint Stock)

Website

https://osvahpharma.com

Company type

Public

Founded year

1966

Operating status

Operating

Headcount range

101–250 employees

Short description

Osveh Pharmaceutical Company is an Iranian public joint-stock pharmaceutical manufacturer (founded 1966) producing branded and specialty generics across cardiovascular, oncology, neurology, and orphan-drug categories for Iran's domestic hospital, pharmacy, and physician channels under Hefadaro Holding.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Pharmaceutical manufacturing
• Specialty medications
• Oncology drugs
• Cardiovascular pharmaceuticals
• Neurology medications

Headquarters

HQ city

Tehran

HQ country

Iran

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Osveh Pharmaceutical Company generates revenue through the manufacture and sale of human pharmaceutical products. The company produces drugs across therapeutic categories including cardiovascular, neurology, nephrology, oncology, hematology, and dietary supplements. Revenue is derived from domestic pharmaceutical distribution through Iran's healthcare supply chain, with the company listed on the Iran Stock Exchange (بورس) indicating publicly traded financial structure.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Osveh Pharmaceutical Company manufactures and supplies a diversified portfolio of human pharmaceutical products in Iran, organized by dosage form (pre-filled syringes, effervescent tablets, ampoules, capsules, tablets, vials) and by therapeutic area (cardiovascular, neurology, nephrology, oncology, hematology, immunosuppression, internal medicine, supplements, and orphan drugs). The company produces branded and exclusive specialty medications, including clopidogrel (Osvix), deferasirox (Osoral), glatiramer acetate (Osvimber), imatinib, and sunitinib (Sunitent), distributed through Iran's pharmaceutical wholesale network to hospitals, pharmacies, and physicians.

Product overview

Osveh Pharmaceutical Company (داروسازی اسوه) is an Iranian publicly-traded pharmaceutical manufacturer established in 1966 (1345 SH). The company operates on an 18,000 square meter facility with 10,580 square meters of built area and produces a diverse portfolio of human pharmaceutical products. The product portfolio is organized across two main classification systems: by dosage form (pre-filled syringes, effervescent tablets, ampoules, capsules, tablets, and vials) and by therapeutic specialty (cardiovascular, neurology/neuropsychiatry, nephrology, oncology & hematology, internal medicine, immunosuppressants, supplements, and orphan drugs). Key branded products include Osvimber (Glatiramer Acetate for MS), Osveral (Deferasirox for iron overload), Osvex (Clopidogrel for cardiovascular), Imatinib, and Sunitent (Sunitinib for oncology). The company positions itself among Iran's top 20 pharmaceutical manufacturers by sales revenue.

Differentiator

Problem solved

Functional benefit

Brands

• Osvex: Critical life-saving drug returned to the Iranian market
• Oswimmer (اسویمر)
• Osoral (اسورال)
• Osvex (اسويكس)
• Sonitent (سونیتنت)

Products and services

• Osvix® (Clopidogrel) / اُسویکس Clopidogrel antiplatelet medication used for cardiovascular disease prevention and treatment. Targeted at physicians, hospitals, and pharmacies in Iran.
• Osoral® (Deferasirox) / اُسورال

Quantifiable outcome

• Ranked among Iran's top 20 pharmaceutical companies by total sales in Tir 1405
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators6 records

Recent moves7 records

Expansion highlights4 records

Regional players

• Gulf Pharmaceutical Industries (Julphar): UAE-based pharmaceutical manufacturer producing branded generics across multiple therapeutic categories for the Middle East and emerging markets. Comparable to Osveh as a regional emerging-market specialty pharma with multi-dosage-form capability.

Broad incumbents

• Dr. Reddy's Laboratories: India-headquartered global pharmaceutical manufacturer producing branded generics and specialty products, including oncology injectables. Comparable to Osveh in producing complex, hard-to-make specialty generics for emerging markets, but at vastly larger global scale.
• Hikma Pharmaceuticals: Jordan-headquartered global pharmaceutical company producing branded and generic specialty products across MENA and the US. Comparable to Osveh in branded-generic, specialty-pharma strategy across multiple therapeutic areas, but operating at much larger scale across geographies.

Direct peers

• Barakat Pharmaceutical Company: Iranian pharmaceutical manufacturer producing branded generics across multiple therapeutic areas, including oncology and specialty products. Comparable to Osveh in being an Iranian specialty pharma focused on branded generics for the domestic market.
• Exir Pharmaceutical Company: Iranian pharmaceutical manufacturer producing sterile injectables, ampoules, vials, and other dosage forms across multiple therapeutic categories. Comparable to Osveh in sterile injectable capability and domestic specialty-pharma positioning.
• Tehran Pharma (TPICO): Iranian pharmaceutical manufacturer producing tablets, capsules, injectables, and other dosage forms across cardiovascular, CNS, and other therapeutic areas. Comparable to Osveh in scale, product mix, public listing, and domestic distribution focus.
• Darou Pakhsh Pharmaceutical Manufacturing Company: One of the largest Iranian pharmaceutical manufacturers, producing branded and generic drugs across multiple therapeutic categories for the domestic market. Directly comparable to Osveh in operating model, GMP manufacturing, multi-dosage-form capability, and public listing in Iran.
• Actoverco Pharmaceutical Company: Iranian pharmaceutical manufacturer producing tablets, capsules, injectables, and other dosage forms for domestic and select export markets. Comparable to Osveh in scale, GMP manufacturing, and branded-generic product strategy.
• Alborz Bulk Pharmaceutical Company: Iranian producer of APIs and finished dosage forms for domestic pharma companies. Comparable to Osveh in Iranian-domestic pharmaceutical manufacturing and being part of a broader holding-company structure.

Emerging players

• CinnaGen Pharmaceutical Company: Iranian biopharmaceutical company producing specialty biologics and biosimilars, including oncology and immunology products. Comparable to Osveh as a domestic Iranian specialty pharma player pushing into higher-complexity therapeutic categories.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/osvah-pharmaceutical-company

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Osveh Pharmaceutical Company